News
SDZNY
83.10
-4.36%
-3.79
Sandoz confirms the EC granted marketing authorization for Bysumlog, Dazparda
TipRanks · 2d ago
Dr. Reddy’s to become first to sell Ozempic generics in Canada
Seeking Alpha · 4d ago
Weekly Report: what happened at SDZNY last week (0504-0508)?
Weekly Report · 6d ago
Jazz, AstraZeneca, Astellas: Foreign Healthcare's strongest Quant picks
Seeking Alpha · 05/07 11:50
CVS to drop J&J's Stelara from its main formularies
Reuters · 05/05 13:11
Sandoz upgraded to Overweight from Equal Weight at Barclays
TipRanks · 05/05 08:10
Sandoz climate targets win SBTi validation for Scope 1 and 2 emissions cuts
PUBT · 05/05 06:23
Positive Report for Sandoz Group Ltd (SDZXF) from Barclays
TipRanks · 05/05 06:17
Weekly Report: what happened at SDZNY last week (0427-0501)?
Weekly Report · 05/04 09:49
Sandoz price target lowered to CHF 65 from CHF 70 at Deutsche Bank
TipRanks · 04/30 18:26
Canada approves generic version of Novo's Ozempic
Seeking Alpha · 04/29 15:14
Regeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD Strength
Seeking Alpha · 04/29 14:29
Sandoz Q1 Net Sales Up 3% At CC; Confirms 2026 Guidance
NASDAQ · 04/29 07:15
Sandoz confirms 2026 outlook for mid-to-high single-digit net sales growth at constant currencies
PUBT · 04/29 05:09
Weekly Report: what happened at SDZNY last week (0420-0424)?
Weekly Report · 04/27 09:50
Harmony Bio spikes after new Wakix patent litigation
Seeking Alpha · 04/21 17:23
Weekly Report: what happened at SDZNY last week (0413-0417)?
Weekly Report · 04/20 09:48
Johnson & Johnson: Why I See Downside Ahead
Seeking Alpha · 04/17 14:42
Sandoz Signs Rwanda Deal To Expand Access To Affordable Medicines Across Africa
NASDAQ · 04/15 17:58
Sandoz signs direct medicines supply agreement with Rwanda government
PUBT · 04/15 06:22
More
Webull provides a variety of real-time SDZNY stock news. You can receive the latest news about Sandoz Group AG through multiple platforms. This information may help you make smarter investment decisions.
About SDZNY
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.